-
Mashup Score: 2(1) Post | LinkedIn - 1 year(s) ago
Univ.-Prof.Dr. Ralph Stephan von Bardeleben Univ.-Professor Interv. Klappentherapie, Head Heart Valve Center, Editor in Chief Echocardiography, Full Professor Interventional Heart Valve Tx Cardiology JGU University of Mainz, ACHD EMAH View full profile
Source: www.linkedin.comCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 0Edwards Announces One-year Data on Transfemoral Transcatheter Tricuspid Valve Replacement - 1 year(s) ago
December 13, 2022 — Edwards Lifesciences Corporation announced that one-year results on patients treated in the single-arm, prospective, global, multi-center TRISCEND study of the company’s EVOQUE transcatheter tricuspid valve replacement system demonstrated favorable safety, efficacy and quality-of-life outcomes. The data were presented during the late-breaking trials session at PCR London…
Source: DAICCategories: Cardiologists, Latest HeadlinesTweet-
@DAICeditor @EdwardsLifesci Edwards Lifesciences announced that one-year results on patients treated in the #TRISCEND study of the company's #EVOQUE #transcatheter #tricuspid #valve_replacement system demonstrated favorable safety, efficacy: https://t.co/amirg8mSDE
-
-
Mashup Score: 5TRISCEND Study: six-month outcomes of transfemoral tricuspid valve replacement in patients with tricuspid regurgitation - 2 year(s) ago
The 6-month follow-up of the TRISCEND study has been presented during the TCT Congress 2021 by principal investigator Dr. Susheel Kodali. A. Sticchi & J. Curio offer PCRonline a review of this trial.
Source: www.pcronline.comCategories: Cardiology News and Journals, Latest HeadlinesTweet-
#TCT2021 coverage: Read this written ✍️🏽 analysis of the #TRISCEND 6 month study results by @Sticchi_Alex & @CurioJonathan. Transfemoral tricuspid valve replacement in patients with TR https://t.co/lfiWZiA2YS #PCRtricuspid #TreatTR #FixTR https://t.co/qFVCLp8M8G
-
-
Mashup Score: 7TCT 2021 - 2 year(s) ago
Educational Grant SupportTCT is sponsored by the Cardiovascular Research Foundation (CRF) and partially funded through educational grants from commercial supporters.This program is made possible in part by the educational grant support of our industry colleagues who, like CRF, are dedicated to educating medical professionals and the public to enhance patient outcomes. CRF gratefully acknowledges…
Source: tct2021.crfconnect.comCategories: Cardiology News and Journals, Latest HeadlinesTweet-
Don't miss the final session of #TCT2021 late-breaking data from #BIORISECHINA #INTREPIDTMVR #TRISCEND and more! Join us at 1:00 PM ET in the Clinical Science Theater. @jgranadacrf @anita_asgar @_WayneBatchelor @JoaoLCavalcante @AskDrMarc https://t.co/Ij76MPH3cL https://t.co/IfLzuEmbvw
-
-
Mashup Score: 6TRISCEND: Tricuspid Valve Replacement System Shows Early Promise - 3 year(s) ago
Based on favorable 30-day technical, safety, and efficacy results from this feasibility study, researchers have started a randomized pivotal trial of the EVOQUE valve replacement system in TRISCEND II.
Source: MedscapeCategories: General Medicine News, Latest HeadlinesTweet-
#ACC21: Based on favorable 30-day technical, safety, and efficacy results from this feasibility #TRISCEND study, researchers have started a randomized pivotal trial of the EVOQUE valve replacement system in #TRISCEND II. https://t.co/R0ape4wuyl https://t.co/udVCKZ1jyb
-
-
Mashup Score: 1TRISCEND: Tricuspid Valve Replacement System Shows Early Promise - 3 year(s) ago
Based on favorable 30-day technical, safety, and efficacy results from this feasibility study, researchers have started a randomized pivotal trial of the EVOQUE valve replacement system in TRISCEND II.
Source: MedscapeCategories: Cardiology News and Journals, Latest HeadlinesTweet-
#ACC21: Based on favorable 30-day technical, safety, and efficacy results from this feasibility study, researchers have started a randomized pivotal trial of the EVOQUE valve replacement system in #TRISCEND II. https://t.co/SMvk2tp4gR https://t.co/HPMXDIBha7
-
-
Mashup Score: 0TRISCEND: Tricuspid Valve Replacement System Shows Early Promise - 3 year(s) ago
Based on favorable 30-day technical, safety, and efficacy results from this feasibility study, researchers have started a randomized pivotal trial of the EVOQUE valve replacement system in TRISCEND II.
Source: MedscapeCategories: Cardiology News and Journals, Latest HeadlinesTweet-
#ACC21: Based on favorable 30-day technical, safety, and efficacy results from this feasibility study, researchers have started a randomized pivotal trial of the EVOQUE valve replacement system in #TRISCEND II. https://t.co/SMvk2tp4gR https://t.co/ham8gyYUUS
-
#PCRLV 2022 opening live cases from #Copenhagen with Lars Sondergaard and #Mainz with @vonBardelebenRS and an #Edwards #Evoque #Tricuspid #replacement #TTVR transvenous transfemoral onging #TRISCEND II trial https://t.co/R4j0EM0woi https://t.co/veDU2YJE6w